Smart Wound Healing Matrix


MUSC researchers have invented a multi-layered system designed to reduce healing time of difficult to heal wounds such as enterocutaneous and enteroatmospheric fistulas, pressure ulcers, diabetic wounds, among others. This multilayer and multifaceted smart wound dressing (SWOD) device addresses many of the limitations of current wound healing strategies: it provides a unidirectional fluid flux barrier layer for wound fluid to egress, an antibacterial layer, induces neovascularization, and reduces the inflammatory response via purinergic signaling blockade to promote and accelerate the healing process. This dressing will induce the regeneration cascade without the need to be removed by using biodegradable materials. No current device incorporates all off these components to affect accelerated closure of difficult to heal wounds. This multilayered system, constituting a smart wound matrix, addresses the limitation of previous wound dressing devices by: (1) Reducing the inflammatory response, (2) providing cues to induce angiogenesis, and cellularization of the wound, and (3) allowing for unidirectional wound exudate drainage and creates a semi-permanent biodegradable wound dressing.

Overview: Non healing, chronic wounds are a tremendous health care burden. According to 2007 data, 3-6 million Americans suffer from non-healing wounds. Health care expenditures for chronic wound care exceed $25B annually, and are eclipsing other chronic medical conditions such as chronic obstructive pulmonary disease. Wound dressing devices are important part of the medical and pharmaceutical wound care market. Traditional wound dressing can be natural or synthetic fibers. The primary purpose is to control wound effluent and prevent bacteria from lodging at the injury site. The utilization of current wound healing devices is labor intensive, cost aversive, induces discomfort, and fails to primarily address many of the factors that contribute to delays in wound healing. Specifically, non-healing wounds are impaired due to poor oxygenation, chronic inflammation, and often infection resulting in degradation of growth factors, poor cell migration, and disruption of the wound healing cycle. Recent literature as well as MUSC publications show that purinergic signaling (ATP signaling) plays a key role in neutrophil attraction and targeting. A novel wound dressing device specifically addressing these issues has the potential to close non-healing wounds with greater efficacy, less expense and with a reduction in patient discomfort.

Applications: Wound healing, enterocutaneous and enteroatmospheric fistulas, pressure ulcer, diabetic wounds, venous leg ulcer

Advantages: Reduces inflammatory response, provides cues to induce angiogenesis and cellularization of the wound, allows for unidirectional wound exudate drainage, and creates a single application biodegradable wound dressing.

Key Words: Wound, dressing, healing, antibacterial, neovascularization, inflammation, purinergic signaling, biodegradable, angiogenesis

Inventors: Michael Yost, Stephen Fann, Matthew Rhett, Veronica Rodriguez-Rivera
Patent Status: PCT Application Filed
MUSC-FRD Technology ID: P1573

Patent Information:
For Information, Contact:
Chelsea Ex-Lubeskie
Licensing Manager, Devices
MUSC Foundation for Research Development
Michael Yost
Stephen Fann
J. Matthew Rhett
Veronica Rodriguez-Rivera
Heather Bainbridge
Sarah Dennis
© 2019. All Rights Reserved. Powered by Inteum